Alteration of transit time and direction of flow to probe the heterogeneous distribution of conjugating activities for harmol in the perfused rat liver preparation
- PMID: 4032287
Alteration of transit time and direction of flow to probe the heterogeneous distribution of conjugating activities for harmol in the perfused rat liver preparation
Abstract
Previous studies in the once-through perfused rat liver preparation have shown that the techniques of normal and retrograde delivery of substrate and computer simulation of enzyme distributions along the sinusoidal flow path in liver were useful in delineating the relative distributions of sulfation and glucuronidation activities for harmol metabolism (Pang et al., J. Pharmacol. Exp. Ther. 224: 647-653, 1983). The observed steady-state hepatic extraction ratios of harmol and the steady-state formation rates of harmol sulfate and harmol glucuronide were consistent with three enzyme-distribution models which described a proximal localization of sulfation activity and a more distal distribution of glucuronidation activities. The present study was a further refinement on the definition of the distribution of these activities. The experimental approach used included the perturbation of delivery of harmol (10 microM) at 8, 12 and 16 ml/min by normal flow, and the alternation of normal and retrograde directional flows for delivery of harmol (10 microM) at constant hepatic blood flows (8, 12 or 16 ml/min) in the single-pass perfused rat liver preparation. The observed steady-state sulfation and glucuronidation rates were compared against predicted values afforded by models previously shown to be adequate and additional enzyme-distributed models. The observed and predicted data point to a periportal distribution of sulfation activity and an even distribution of glucuronidation activity for the metabolism of harmol.
Similar articles
-
Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activities of harmol in the perfused rat liver preparation.J Pharmacol Exp Ther. 1983 Mar;224(3):647-53. J Pharmacol Exp Ther. 1983. PMID: 6827487
-
Kinetics of sulfation and glucuronidation of harmol in the perfused rat liver preparation. Disappearance of aberrances in glucuronidation kinetics by inhibition of sulfation.Biochem Pharmacol. 1982 Oct 1;31(19):3023-8. doi: 10.1016/0006-2952(82)90074-0. Biochem Pharmacol. 1982. PMID: 7150332
-
Cholestatic effect of harmol glucuronide in the rat. Prevention of harmol-induced cholestasis by increased formation of harmol sulfate.J Pharmacol Exp Ther. 1982 Jun;221(3):731-4. J Pharmacol Exp Ther. 1982. PMID: 7086685
-
Metabolism of harmol and transport of harmol conjugates in isolated rat hepatocytes.Drug Metab Dispos. 1983 Sep-Oct;11(5):433-40. Drug Metab Dispos. 1983. PMID: 6138228
-
A new model-independent physiological approach to study hepatic drug clearance and its applications.Int J Clin Pharmacol Ther Toxicol. 1984 Nov;22(11):577-90. Int J Clin Pharmacol Ther Toxicol. 1984. PMID: 6389376 Review.
Cited by
-
Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver.J Pharmacokinet Biopharm. 1989 Dec;17(6):645-71. doi: 10.1007/BF01062123. J Pharmacokinet Biopharm. 1989. PMID: 2635738
-
A Complete Extension of Classical Hepatic Clearance Models Using Fractional Distribution Parameter fd in Physiologically Based Pharmacokinetics.J Pharm Sci. 2024 Jan;113(1):95-117. doi: 10.1016/j.xphs.2023.05.019. Epub 2023 Jun 4. J Pharm Sci. 2024. PMID: 37279835 Free PMC article.
-
Competition between two enzymes for substrate removal in liver: modulating effects due to substrate recruitment of hepatocyte activity.J Pharmacokinet Biopharm. 1987 Oct;15(5):473-96. doi: 10.1007/BF01061758. J Pharmacokinet Biopharm. 1987. PMID: 3694493
-
A review of metabolite kinetics.J Pharmacokinet Biopharm. 1985 Dec;13(6):633-62. doi: 10.1007/BF01058905. J Pharmacokinet Biopharm. 1985. PMID: 3914545 Review.
-
A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination.J Pharmacokinet Biopharm. 1992 Apr;20(2):105-45. doi: 10.1007/BF01070998. J Pharmacokinet Biopharm. 1992. PMID: 1629793